Molecular Mechanisms of Synergistic Effect of PRIMA‐1met and Oxaliplatin in Colorectal Cancer With Different p53 Status

ABSTRACT Background The toxicity and drug resistance associated with oxaliplatin (L‐OHP) limit its long‐term use for colorectal cancer (CRC) patients. p53 mutation is a common genetic trait of CRC. PRIMA‐1met (APR‐246, eprenetapopt) restores the DNA‐binding capacity of different mutant P53 proteins....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer medicine (Malden, MA) MA), 2025-01, Vol.14 (1), p.e70530-n/a
Hauptverfasser:	Li, Xiao‐lan, Zhou, Jianbiao, Tang, Nicole Xin‐Ning, Chai, Yi, Zhou, Meng, Gao, Ai‐di, Lu, Zhong‐kai, Min, Han
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Cancer therapies Cell cycle Cell growth Cell migration Cell viability Chemotherapy Cholecystokinin Colorectal cancer colorectal cancer (CRC) Colorectal carcinoma combination therapy Cytotoxicity DNA damage Drug resistance hematologic toxicity Leukemia Metastasis Molecular modelling Mortality Mutants Mutation Oxaliplatin oxaliplatin (L‐OHP) p53 Protein p53 tumor suppressor gene PRIMA‐1met Tumorigenesis Variance analysis Wound healing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!